Conversion therapies for initially unresectable hepatocellular Carcinoma

被引：0
|
作者：
Fritsch, J. [1 ]
Ardelt, M. [1 ]
Settmacher, U. [1 ]
机构：
[1] Univ Klinikum Jena, Klin Allgemein Viszeral & Gefasschirurg, Klinikum 1, D-07747 Jena, Germany
来源：
CHIRURGIE | 2025年 / 96卷 / 01期
关键词：
D O I：
10.1007/s00104-024-02207-6
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：65 / 66
页数：2
相关论文
共 50 条
  • [21] PRICE ANALYSIS OF CANCER THERAPIES FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA
    Williams, A.
    Anderson, N.
    Gwon, Y. G.
    Wifler, W.
    VALUE IN HEALTH, 2022, 25 (01) : S7 - S7
  • [22] Multicenter prospective study to evaluate the efficacy of lenvatinib to achieve conversion surgery for initially unresectable hepatocellular carcinoma: LENS-HCC trial
    Tada, Masaharu
    Ichida, Akihiko
    Arita, Junichi
    Hatano, Etsuro
    Eguchi, Susumu
    Saiura, Akio
    Nagano, Hiroaki
    Shindoh, Junichi
    Hashimoto, Masaji
    Takemura, Nobuyuki
    Taura, Kojiro
    Sakamoto, Yoshihiro
    Takahashi, Yu
    Seyama, Yasuji
    Sasaki, Yasuharu
    Uemura, Kohei
    Kokudo, Norihiro
    Hasegawa, Kiyoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [23] The Impact of Sequential Therapies after First-Line Systemic Therapies in Unresectable Hepatocellular Carcinoma
    Lee, Shou-Wu
    Lee, Teng-Yu
    Yang, Sheng-Shun
    Huang, Yi-Jie
    Peng, Yen-Chun
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (09)
  • [24] Clinical Features and Outcomes of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma
    Tomonari, Tetsu
    Tani, Joji
    Sato, Yasushi
    Tanaka, Hironori
    Tanaka, Takahiro
    Taniguchi, Tatsuya
    Kawano, Yutaka
    Morishita, Asahiro
    Okamoto, Koichi
    Sogabe, Masahiro
    Miyamoto, Hiroshi
    Masaki, Tsutomu
    Takayama, Tetsuji
    CANCERS, 2023, 15 (21)
  • [25] From Conversion to Resection for Unresectable Hepatocellular Carcinoma: A Review of the Latest Strategies
    Liang, Chen
    He, Zhaoqian
    Tao, Qiang
    Tang, Xiang
    Jiang, Lingmin
    Tu, Xinyue
    Liu, Zonghao
    Chen, Hua
    Xie, Feihu
    Zheng, Yun
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (24)
  • [26] Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials - I: hepatic arterial embolization and embolization-based therapies in unresectable hepatocellular carcinoma
    Reidy, DL
    Schwartz, JD
    ANTI-CANCER DRUGS, 2004, 15 (05) : 427 - 437
  • [27] Recent advances in systemic therapies for unresectable hepatocellular carcinoma and their impact on clinical outcomes
    Oura, Kyoko
    HEPATOLOGY RESEARCH, 2025, 55 (02) : 163 - 165
  • [28] Yttrium-90 radiation lobectomy for initially unresectable hepatocellular carcinoma: A treatment paradigm shift?
    Fong, Zhi Ven
    Qadan, Motaz
    SURGERY, 2021, 169 (05) : 1052 - 1053
  • [29] Efficacy and safety of curative hepatectomy after conversion therapies for initial unresectable hepatocellular carcinoma: A multicenter propensity score matching study
    Mai, R-Y.
    Guo, L.
    Liang, R.
    Wang, X-B.
    Bai, T.
    Chen, J.
    Lin, Z.
    Lin, Y.
    Wu, G.
    Xiang, B-D.
    Ma, L.
    Wu, F-X.
    Li, L-Q.
    Guo, W-X.
    Ye, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S612 - S613
  • [30] Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors
    Li, Xingzhi
    Chen, Jie
    Wang, Xiaobo
    Bai, Tao
    Lu, Shaolong
    Wei, Tao
    Tang, Zhihong
    Huang, Chengwen
    Zhang, Bin
    Liu, Bowen
    Li, Lequn
    Wu, Feixiang
    FRONTIERS IN ONCOLOGY, 2023, 13
12345